We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is FULGENT GENETIC (FLGT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of FULGENT GENETIC (FLGT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
FULGENT GENETIC is one of 977 individual stocks in the Medical sector. Collectively, these companies sit at #16 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. FLGT is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for FLGT's full-year earnings has moved 128.70% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, FLGT has moved about 102.34% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.90%. This means that FULGENT GENETIC is performing better than its sector in terms of year-to-date returns.
To break things down more, FLGT belongs to the Medical Info Systems industry, a group that includes 32 individual companies and currently sits at #220 in the Zacks Industry Rank. On average, this group has gained an average of 6.93% so far this year, meaning that FLGT is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track FLGT. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is FULGENT GENETIC (FLGT) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of FULGENT GENETIC (FLGT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
FULGENT GENETIC is one of 977 individual stocks in the Medical sector. Collectively, these companies sit at #16 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. FLGT is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for FLGT's full-year earnings has moved 128.70% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, FLGT has moved about 102.34% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.90%. This means that FULGENT GENETIC is performing better than its sector in terms of year-to-date returns.
To break things down more, FLGT belongs to the Medical Info Systems industry, a group that includes 32 individual companies and currently sits at #220 in the Zacks Industry Rank. On average, this group has gained an average of 6.93% so far this year, meaning that FLGT is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track FLGT. The stock will be looking to continue its solid performance.